The United States of America As Represented by the Department of Health

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America

University of South Florida

Burt E Anderson

Russell L Regnery

Jacqueline E Dawson

Edward Turos

Ryan Scott Cormier

Rebecca J Kapolka

Glenn Roma

John C Thomas

species are facultative intracellular pathogens responsible for a range of diseases in animals and in humans. A selection of N-acyl ciprofloxacin analogues, chemically synthesized from ciprofloxacin, have been tested in vitro for activity againstspecies as models for therapeutic development. Ninestrains, including five of, two of, and one each ofand, have been tested for susceptibility to different N-acyl ciprofloxacin derivatives. Several techniques have been used to test the in vitro antibacterial activity of the derivatives. Seven of them, labeled RC4-125, RC4-143, RC4-147, RC5-28, RC5-29, RC5-32 and RC5-69 showed significant intracellular anti-activity. These synthetically derived N-acyl ciprofloxacin derivatives may be useful in the therapeutic treatment of infections caused by

Activity of new N-acylated ciprofloxacin derivatives against faculative intracellular bacteria

A new isolate of Ehrlichia species has been obtained from a patient suffering from ehrlichiosis. The new isolate has been found to be similar, but distinctly different from . A diagnostic kit and methods for diagnosing ehrlichiosis in humans and for screening drugs toxic to the new isolate have been described.

Identification of a new ehrlichia species from a patient suffering from ehrlichiosis

Fusion protein compositions containing the sequence of a 17 kilodalton antigenic polypeptide of Rochalimaea (SEQ ID NO:12) are disclosed for diagnosis of cat scratch disease and bacillary angiomatosis by detection of antibodies specifically binding to the polypeptide.

Compositions for diagnosing Rochalimaea henselae and Rochalmaea quintana infection

A new isolate of Ehrlichia species has been obtained from a patient suffering from ehrlichiosis. The new isolate has been found to be similar, but distinctly different from E. canis. A diagnostic kit and methods for diagnosing ehrlichiosis in humans and for screening drugs toxic to the new isolate have been described.

Identification of a new Ehrlichia species from a patient suffering from

A method of diagnosing cat scratch disease and a method of diagnosing bacillary angiomatosis in a subject by detecting the presence of Rochalimaea henselae or an antigenic fragment thereof in the subject is provided. Also provided is a vaccine comprising an immunogenic amount of a nonpathogenic Rochalimaea henselae or an immunogenically specific determinant thereof and a pharmaceutically acceptable carrier. A method of diagnosing Rochalimaea quintana infection in a subject by detecting the presence of a nucleic acid specific to Rochalimaea quintana in a sample from the subject is provided. A purified, 60-kDa heat shock protein of Rochalimaea is provided. Also provided is a 17-kDa antigenic polypeptide of Rochalimaea.

Nucleic acids of Rochalimaea henselae and methods and compositions for

A method of diagnosing cat scratch disease and a method of diagnosing bacillary angiomatosis in a subject by detecting the presence of Rochalimaea henselae or an immunogenically specific determinant thereof in the subject is provided. Also provided is a vaccine comprising an immunogenic amount of a nonpathogenic Rochalimaea henselae or an immunogenically specific determinant thereof and a pharmaceutically acceptable carrier. A method of diagnosing Rochalimaea quintana infection in a subject by detecting the presence of a nucleic acid specific to Rochalimaea quintana in a sample from the subject is provided. A purified heat shock protein of Rochalimaea is provided.

Nucleic acids specific for Rochalimaea quintana

Compositions for diagnosing rochalimaea henselae and rochalimaea

A new isolate of Ehrlichia species has been obtained from a patient suffering from ehrlichiosis. The new isolate has been found to be similar, but distinctly different from E. canis. The new isolate is E. chaffeensis and is contained in a cell line of canine macrophage cells on deposit with the American Type Culture Collection under accession number CRL 10679. The new isolate must be contained in a cell line in order to remain viable but may be isolated from the cell line. However, the isolate will not remain viable outside of the cell line. A diagnostic kit and methods for diagnosing ehrlichiosis in humans and for screening drugs toxic to the new isolate have also been desclosed.

Ehrlichia species from a patient suffering from ehrlichiosis

The present invention relates to a method of diagnosing cat scratch disease and a method of diagnosing bacillary angiomatosis in a subject by detecting the presence of Rochalimaea henselae or an immunogenically specific determinant thereof in the subject. Also provided by the present invention is a vaccine comprising an immunogenic amount of a nonpathogenic Rochalimaea henselae or an immunogenically specific determinant thereof and a pharmaceutically acceptable carrier.

Growing community of inventors

Valrico, FL, United States of America

Burt E Anderson